A team based at Osaka University has conducted the first ever transplant of cardiac muscle cells generated from iPS cells, around the globe, in a clinical trial initiated physician.
A professor in the university’s cardiovascular surgery unit, Yoshiki Sawa, together with his colleagues at the university, in a clinical procedure to verify the efficiency and security of the therapy with the help of induced pluripotent stem cells, intend to transplant heart muscle cell sheets over the time of 3 years into 10 individuals undergoing severe heart malfunction a result of ischemic cardiomyopathy.
The team conducted, the present month, an operation on an individual, in an attempt to take a first step into the project. This operation was successful. The individual has now been moved to a general ward.
It is predicted that the cells on the degradable sheets which attach to the heart’s surface will grow and eliminate a protein which has the power to regenerate blood vessels and advance cardiac function. Already, the iPS cells have been stored after being taken from the blood cells of healthy donors.
Every sheet that goes on the heart’s surface is 4 to 5 centimeters in width, and 0.1 millimeter in thickness.
The team from Osaka University will be observing the patient throughout the year.
At a news conference, Yoshiki Sawa expressed his hopes of the transplant becoming the medical technology that succeeds in saving as many individuals as it can, since he has come across many lives that he was unable to save.
On Monday, the university’s researchers stated how they chose to carry out a clinical trial in a clinical research’s stead so they could gain timely approval from the health ministry for clinical applications.